Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472033 | 1.00 | CNR1 (0.56) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL13763216 | 1.00 | CNR1 (0.56) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4472030 | 1.00 | CNR1 (0.56) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL13757019 | 0.90 | CNR1 (0.58) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4492964 | 0.90 | CNR1 (0.58) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4492968 | 0.90 | CNR1 (0.58) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4477029 | 0.89 | CNR1 (0.67) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4492938 | 0.85 | CNR1 (0.75) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4485823 | 0.85 | CNR1 (0.62) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 | |
| SCHEMBL4480047 | 0.84 | CNR1 (0.59) | CNR1CYP3A4CYP2C9CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1891068-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| WO-2006138695-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | CNR1 1/4885CYP3A4 572/4885CYP2C9 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.